Evidence map›Paper›PMID 29020219›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018

Epidemiology and Antimicrobial Resistance Characteristics of the Sequence Type 131-H30 Subclone Among Extraintestinal Escherichia coli Collected From US Children.

Arianna Miles-Jay, Scott J Weissman, Amanda L Adler, Veronika Tchesnokova, Evgeni V Sokurenko, Janet G Baseman, Danielle M Zerr

Abstract readMulticenter Study
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Arianna Miles-JayDepartment of Epidemiology, University of Washington, Seattle.
Scott J WeissmanSeattle Children's Research Institute, Seattle.
Amanda L AdlerSeattle Children's Research Institute, Seattle.
Veronika TchesnokovaDepartment of Microbiology, University of Washington, Seattle.
Evgeni V SokurenkoDepartment of Microbiology, University of Washington, Seattle.
Janet G BasemanDepartment of Epidemiology, University of Washington, Seattle.
Danielle M ZerrSeattle Children's Research Institute, Seattle.

Funding

National surveillance of emerging MDR in pediatric Enterobacteriaceae infectionsR01AI083413 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI WEISSMAN, SCOTT J, ZERR, DANIELLE M · 2010 to 2013
$2.3M
Institute of Translational Health SciencesTL1TR000422 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$2.1M
NCATS NIH HHS TL1 TR000422NIAID NIH HHS R01 AI083413
6 · The paper itself

Abstract

Background: Escherichia coli sequence type (ST) 131-H30 is a globally important pathogen implicated in rising rates of multidrug resistance among E. coli causing extraintestinal infections. Previous studies have focused on adults, leaving the epidemiology of H30 among children undefined. Methods: We used clinical data and isolates from a case-control study of extended-spectrum cephalosporin-resistant E. coli conducted at 4 US children's hospitals to estimate the burden and identify host correlates of infection with H30. H30 isolates were identified using 2-locus genotyping; host correlates were examined using log-binomial regression models stratified by extended-spectrum cephalosporin resistance status. Results: A total of 339 extended-spectrum cephalosporin-resistant and 1008 extended-spectrum cephalosporin-susceptible E. coli isolates were available for analyses. The estimated period prevalence of H30 was 5.3% among all extraintestinal E. coli isolates (95% confidence interval [CI], 4.6%-7.1%); H30 made up 43.3% (81/187) of extended-spectrum β-lactamase (ESBL)-producing isolates in this study. Host correlates of infection with H30 differed by extended-spectrum cephalosporin resistance status: Among resistant isolates, age ≤5 years was positively associated with H30 infection (relative risk [RR], 1.83 [95% CI, 1.19-2.83]); among susceptible isolates, age ≤5 years was negatively associated with H30 (RR, 0.48 [95% CI, .27-.87]), while presence of an underlying medical condition was positively associated (RR, 4.49 [95% CI, 2.43-8.31]). Conclusions: ST131-H30 is less common among extraintestinal E. coli collected from children compared to reported estimates among adults, possibly reflecting infrequent fluoroquinolone use in pediatrics; however, it is similarly dominant among ESBL-producing isolates. The H30 subclone appears to disproportionately affect young children relative to other extended-spectrum cephalosporin-resistant E. coli.

Indexed as

AdolescentAnti-Bacterial AgentsCase-Control StudiesCephalosporinsChildChild, PreschoolDNA, BacterialDrug Resistance, Multiple, BacterialEscherichia coli InfectionsExtraintestinal Pathogenic Escherichia coliFemaleHumansInfantInfant, NewbornMalePrevalenceAnti-Bacterial AgentsCephalosporinsDNA, Bacterialantimicrobial resistanceE. coli infectionspediatric infectionsST131

Identifiers

PMID29020219
PMCPMC5848265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.